67 PEG-loxenatide, Chinas first long-acting GLP-RA product, was approved for marketing in China in May 2019
The answer lies in the following: Ozempic is more stable than endogenous GLP-1: Where the naturally produced GLP-1 breaks down within a few minutes by bodily enzymes, Ozempic can last for a week (thats why it is injected once weekly) due to modifications in its molecule
Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
Behavior change must occur alongside the medication for sustained success
For anyone ready to act on their health now, an approved, medically supervised option is the responsible path and its one we can start with you
By Molecule Class, Semaglutide Leads Today but Cedes Leadership by 2035 Semaglutide holds a commanding 58% share of the obesity GLP-1 market in 2025, underpinned by robust clinical validation from the STEPandSELECT trials, proven cardiovascular benefits, and extensive real-world use
.png)
